e-learning
resources
Berlin 2008
Monday, 06.10.2008
Interstitial lung disease in systemic and vascular disorders
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease
B. Terrier, M. Tamby, L. Camoin, A. Berezne, P. Guilpain, N. Tamas, M. Humbert, G. Simonneau, C. Broussard, L. Guillevin, L. Mouthon (Paris, Clamart, France)
Source:
Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Session:
Interstitial lung disease in systemic and vascular disorders
Session type:
Thematic Poster Session
Number:
1895
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Terrier, M. Tamby, L. Camoin, A. Berezne, P. Guilpain, N. Tamas, M. Humbert, G. Simonneau, C. Broussard, L. Guillevin, L. Mouthon (Paris, Clamart, France). Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease. Eur Respir J 2008; 32: Suppl. 52, 1895
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc)
Source: Eur Respir J 2005; 26: Suppl. 49, 202s
Year: 2005
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
Source: Eur Respir J 2011; 38: 1355-1360
Year: 2011
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis
Source: Eur Respir J 2006; 28: Suppl. 50, 95s
Year: 2006
Autoantibodies to the surfactant protein D in patients with interstitial lung diseases associated with amyopathic dermatomyositis and systemic sclerosis
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017
Year: 2018
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
CCL18 as marker of disease progression in systemic sclerosis
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012
Pulmonary involvement in systemic sclerosis
Source: Eur Respir Monogr 2019; 86: 90-105
Year: 2019
Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Nine cases of interstitial lung disease associated with anti-CADM140 antibody positive dermatomyositis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Histology is not a prognostic indicator in patients with interstitial pneumonias associated with systemic sclerosis
Source: Eur Respir J 2001; 18: Suppl. 33, 526s
Year: 2001
Utility of myositis related antibodies in interstitial lung disease and suspected autoimmunity.
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept